| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial− FRUZAQLA (fruquintinib) is the First Novel Targeted ...
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showc...
This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in ...
Results will be presented from the registration Phase II study of fruquintinib combined with sintilimab in 98 second-line or ab...
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from ...
HMPL-306 is a novel dual-inhibitor of IDH1 and IDH2 enzymes. Mutations of IDH1 and IDH2 have been implicated as drivers of cert...
Almost half a million people diagnosed each year across the globe — Collaboration based on synergistic potential of inhibiti...
